Imcyse SA

🧡 Join the Movement for Autoimmune Awareness! 🧡   Did you know that autoimmune diseases affect millions worldwide, yet often go unnoticed due to their invisible symptoms? From Type 1 Diabetes (#T1D) to Multiple Sclerosis (#MS) and Neuromyelitis Optica (#NMO), autoimmune diseases come in many forms, each presenting its own set of challenges.   At Imcyse SA we are working hard to develop a new class of specific immunotherapies, #Imotopes, that could revolutionize the treatment of these diseases. Our robust pipeline currently comprises clinical-stage programs in T1D and MS as well as pre-clinical programs in NMO, Celiac disease and Rheumatoid arthritis (#RA).   Today we want to shed light on these conditions and support those battling them every day! 💪   #AutoimmuneAwareness #Type1Diabetes #MultipleSclerosis #NeuromyelitisOptica  

We are thrilled to announce the appointment of Christel Lonneux to the role of Finance and HR Director at Imcyse SA!   Since joining us in January 2022, Christel has demonstrated exceptional dedication and expertise in the areas of finance and employee management. With over 14 years of corporate auditing experience, including a decade at PwC, she brings invaluable insights into her new role. This milestone highlights her commitment to excellence and will be instrumental in our continued growth.   Congratulations, Christel!   #TeamImcyse #Promotion

We are excited to take part at the "Data Privacy for Health 2024" event! 🌐💻   Jean Van Rampelbergh, Chief Clinical Development Officer (CCDO) of Imcyse SA, will be joining the e-Research Round Table on Tuesday, January 23, at 9:30 am CET. There he will discuss, together with other experts in the field, the future of digital clinical research.   This will be an invaluable opportunity to connect with industry experts, exchange insights, and stay ahead in safeguarding sensitive healthcare information.   #HealthDataPrivacy #Innovation #DataSecurity 🚀🔐

Multiple Sclerosis (MS) – the disease of a thousand faces. We invite you to dive into the latest Open Access Government article, where Prof. Dr. Bart Van Wijmeersch and patient advocate Ann Vanoirbeek explain the current therapeutic landscape of #MS and discuss potential advancements that could revolutionize patient treatment. Prof. Bart Van Wijmeersch explained “with [the] Imotope technology, [Imcyse] aim[s] to target only the immune cells that are destroying the myelin while leaving the other parts of the immune system functioning - restoring the immune system balance, rather than suppressing it.” Read more (pages 136-137): https://lnkd.in/d4SdsNHB #immunotherapy #autoimmunediseases #multiplesclerosis

We are excited to start the new year in San Francisco this January during the 2024 J.P. Morgan week!   Join Denis Bedoret CEO and Andrew Mackie CBO of Imcyse SA, for in depth discussions around scientific, clinical and commercial opportunities.   Don’t hesitate to request a meeting with us via:   👉 bd@imcyse.com   #JPMorgan2024 #Partnering

🌟 Today on #WorldDiabetesDay, we stand together to emphasize the crucial need for universal access to diabetes care. Millions worldwide require ongoing support and access to necessary resources to effectively manage their condition and prevent complications. At Imcyse SA we continue to do our part in the fight against type 1 diabetes (#T1D), an #autoimmunedisease that affects over 9 million individuals worldwide. Early detection is key to minimizing any severe complications. However, patients are still subjected to regular monitoring of blood glucose levels and daily insulin injections, which can deteriorate their quality of life. With IMCY-0098, our novel insulin-based #Imotope, we seek to intervene early enough in the autoimmune response to stop the destruction of insulin-producing beta cells while maintaining the ability of the pancreas to naturally produce insulin. Our goal is to enable a future where daily injections are not needed anymore. #AccessToDiabetesCare #DiabetesAwareness #type1diabetes

We are thrilled to have been a part of #BIOEurope2023! Energizing discussions and valuable connections—all contributing to the advancement of biotech and life sciences. Andrew Mackie, CBO of Imcyse SA, also talked to MC Services AG and discussed the upcoming milestones of the Company. To learn more, follow the link: https://lnkd.in/dnTKBivi

#BioEurope2023 is taking place next week, November 6 - 8, in Munich, Germany!   Join Andrew Mackie, CBO of Imcyse SA, and gain insight into our pre-clinical and clinical programs. We are very much looking forward to connecting with industry leaders, innovative tech players and investors. Schedule a meeting with us through the partnering system and learn more about our unique #Imotope platform: https://lnkd.in/gRkjn8M